What the Wegovy Price Increase Really Means for UK Private Patients

The biggest myth: the price you saw six months ago is still the going rate

A lot of people searching this topic are hoping the answer is no, the increase did not really happen. It did. Novo Nordisk's pricing arrangements with UK private dispensers shifted noticeably through 2025, and the effect is visible across the market. Wegovy had been available privately at prices that, in retrospect, were not sustainable once NHS demand began to scale and supply chains tightened. The correction has been substantial.

For context, it is worth noting what happened on the tirzepatide side at the same time: Eli Lilly raised Mounjaro's UK list price from around £122 to around £330 per four-week pen from 1 September 2025, as widely reported. The Wegovy trajectory followed a similar upward direction, though the starting point and landing point differ by dose. Private providers now typically quote Wegovy at prices that reflect this changed supply cost rather than the earlier, lower figures that circulated online. If you find a price that looks significantly cheaper than the broad market, that gap deserves scrutiny, not celebration.

A question our prescribers hear most weeks is whether there is a way to lock in an older price or find a discount code. There is not, and that framing misunderstands how prescription medicine pricing works. The cost of the medicine itself is only one element; a legitimate price also has to cover clinical oversight, which is legally required for a POM.

If you are wondering whether Wegovy is continuing to increase in price, that question is one we address in detail, covering the market forces and Novo Nordisk's arrangements that are driving the direction of costs. For a fuller timeline of what shifted and when, the 2025 price changes explained sets out the sequence in detail.

What headline prices often leave out

Quoted prices for Wegovy vary across providers, and not all of them are quoting the same thing. Some figures represent the medicine only; others bundle services to varying degrees. The difference matters because the following are all real costs that some providers charge separately: an initial consultation fee, an ongoing prescription fee charged per repeat, a delivery charge per order, and access to clinical support if something goes wrong or your dose needs reviewing.

Taken together, those add-ons can shift the total cost of a month's treatment considerably above the headline number. A lower opening price with £30 delivery plus a consultation fee at each repeat can end up more expensive than a higher all-in price with no extras, and it often comes with less clinical contact, which is the thing that makes the treatment safe to use.

It is also worth checking whether the price covers the dose you actually need. Starter-dose pricing, at the lowest 0.25mg titration step, tends to be quoted because it looks accessible. Maintenance-dose pricing is usually higher. If a provider does not make that distinction clear upfront, ask directly, and if you want a specific example of how mid-titration costs land, our breakdown of the Wegovy 1 mg price explains what that particular dose typically costs and what is included. For a broader breakdown of how Wegovy pricing works across doses and what each figure typically includes, our Wegovy price guide walks through the structure plainly.

You can also read about whether prices have started to soften on our page on whether a Wegovy price decrease is in prospect, which covers the factors that could influence costs over the next year.

Where nume sits, and why we price the way we do

We are not going to pretend we are the cheapest option out there. We are not, and that is a deliberate choice. The price at nume covers exactly one thing: everything. That means the clinical consultation, the prescription, the treatment itself, and free next-working-day delivery through DPD in plain unbranded packaging. There are no consultation fees charged separately, no prescription fees bolted on at repeat, no delivery charge, and no aftercare that expires after your first pen. Clinical support is available seven days a week and is staffed by the same GPhC-registered prescribers who approved your treatment.

Every repeat order goes through a fresh clinical review before anything is dispatched. That is not a selling point we invented; it is the standard that GPhC guidance requires and that our pharmacy, registered under premises number 9012878 on the GPhC register, is built around. You can verify that registration directly.

The current price for treatment is shown on our treatments page, which is where pricing lives, not buried in body copy. If you want to understand what is included before you check the number, our about page explains the service structure in full.

Why 'cheapest' is not the right question for a prescription medicine

The MHRA has been explicit on this. Counterfeit Wegovy and other GLP-1 pens have been seized in large volumes across the UK, and the agency's public warnings make clear that unusually low prices are a reliable red flag for medicines supplied through illegal channels. Some fake pens have contained insulin rather than semaglutide, a potentially dangerous substitution. The counterfeit risk is not theoretical; it drove significant enforcement action throughout 2024 and 2025. You can report suspected fake or unlicensed sellers via the MHRA's Yellow Card scheme.

NICE's recommendation for semaglutide (Wegovy), set out in technology appraisal TA875, covers treatment within a clinically supervised pathway, because the evidence base was built inside that kind of structure. Removing clinical oversight to save money does not just reduce the service; it changes what the medicine is, in terms of safety.

The right question is not which provider charges the least, but which provider can demonstrate that the supply chain is legitimate, the prescriber is qualified and registered, and ongoing clinical contact is genuinely available. Those things are verifiable. Whether you can save £15 on a pen is much less important.

If you are weighing up whether Wegovy or tirzepatide (Mounjaro) is the better fit clinically, our Wegovy overview sets out the evidence and licensing position for both. Or if you are ready to talk to a prescriber directly, starting a free consultation is the next step.